Skip to main content
Physical/Tech

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease.

| Source: The New England journal of medicine

The inflammatory cytokine interleukin-6 is hypothesized to be a therapeutic target for patients with atherosclerotic cardiovascular disease and chronic kidney disease. Whether neutralizing interleukin-6 levels with ziltivekimab, a monoclonal antibody, reduces the risk of adverse cardiovascular events remains unknown. We conducted a multinational, double-blind, randomized, placebo-controlled trial involving adults with established atherosclerotic cardiovascular disease, chronic kidney disease, an

The inflammatory cytokine interleukin-6 is hypothesized to be a therapeutic target for patients with atherosclerotic cardiovascular disease and chronic kidney disease. Whether neutralizing interleukin-6 levels with ziltivekimab, a monoclonal antibody, reduces the risk of adverse cardiovascular events remains unknown. We conducted a multinational, double-blind, randomized, placebo-controlled trial involving adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation (defined by a high-sensitivity C-reactive protein [CRP] level of ≥2 mg per liter). Patients were randomly assigned in a 1:1 ratio to receive subcutaneous ziltivekimab (15 mg once monthly) or placebo. The primary efficacy end point was a 3-point major adverse cardiovascular event (MACE). This composite end point included death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. A total of 6376 patients were included in the full analysis population: 3184 were assigned to receive ziltivekimab and 3192 to receive placebo. The mean age of the patients was 69.4 years, and 27.5% were women. At 24 months, the between-group difference in the median percent change in the levels of inflammatory biomarkers among patients receiving ziltivekimab as compared with those receiving placebo was -76 percentage points for free interleukin-6 and -64 percentage points for high-sensitivity CRP. During a median follow-up of 33 months, a primary end-point event occurred in 561 patients (17.6%) in the ziltivekimab group and in 565 patients (17.7%) in the placebo group (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11; P = 0.84). Serious adverse events occurred in 54.6% of the patients in the ziltivekimab group and in 54.8% of those in the placebo group; serious infections occurred in 20.4% and 17.9%, respectively. Among patients with atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation, a strategy of lowering interleukin-6 levels with ziltivekimab did not result in a lower risk of cardiovascular events than placebo. (Funded by Novo Nordisk; ZEUS ClinicalTrials.gov number, NCT05021835.).

Read the original source →

Related Stories

Physical/Tech

Intuitive knowledge of object acoustics enables perceptual separation of physical variables from impact sounds.

Upon hearing objects collide, humans can estimate physical attributes such as material and mass. Although the physics of sound generation is well established, the inverse problem that listeners solve-of inferring physical parameters from sound-remains poorly understood. Classical accounts posit the use of acoustic cues that correlate with physical variables but do not explain how humans might distinguish multiple concurrent physical causes. To study this problem, we measured impulse responses fr

Continue reading
Physical/Tech

Sub-ice thermal gradients strongly influence winter depth use of an iconic cold-water fish.

In a thermally stratified lake, freshwater fish select habitats that align with their thermal preferences. While most studies of dimictic lakes have focused on habitat selection during summer stratification, less attention has been given to winter when inverse thermal stratification occurs with water temperatures between 0 to 4 °C. Our results show that winter thermal stratifications vary considerably among lakes. Much of the variation in winter depth use by the cold-water predator, Lake Tr

Continue reading
Physical/Tech

Emergent long-tailed dynamics in spin ice.

In this study, we reveal long-tail dynamics spontaneously arising from a magnetic system. Specifically, we consider a classical spin system and demonstrate the emergence of a spin-ice physics when drive-induced heating is well suppressed. We show that at high driving frequencies, magnetic monopole excitations exhibit nonergodic stochastic dynamics characterized by power-law-distributed trapping times with long tails-a behavior that persists even in the absence of driving. At intermediate driving

Continue reading
Physical/Tech

People know who to ask for favors despite underestimating compliance.

Whether and how people approach social interactions hinges on how they expect others to respond. Extensive social psychology research suggests that people are inaccurate interpersonal perceivers, overestimating negative responses (e.g., discomfort) and underestimating positive responses (e.g., appreciation) across a variety of social situations. However, this conclusion is based almost exclusively on mean-level bias analyses that obscure the dyadic nature of interpersonal judgment and rely on a

Continue reading
Physical/Tech

Mapping the Slow Propagation of Disorder across a Photoreceptor's Tertiary Structure with Time-Resolved Crystallography.

Order-disorder transitions allow many proteins to shift between compact and flexible/unfolded states, thereby acting as structural switches that regulate catalysis, signaling, recognition, and allostery. We applied time-resolved serial oscillation crystallography to establish the structural kinetics of the light-triggered order-disorder transition of an animal-like cryptochrome as a six-second-long molecular movie with near-atomic all-residue spatial resolution and millisecond temporal resolutio

Continue reading